dimostat (SP-1-161) / Shuttle Pharma - LARVOL DELTA

Shuttle Pharma Expands Patent Coverage on HDAC Inhibitor Platform (PRNewswire) - "Shuttle Pharmaceuticals Holdings, Inc...announced the expansion of its patent portfolio following the issuance of a Canadian patent for its Histone Deacetylase (HDAC) inhibitor platform technology titled 'Dual Function Molecules for Histone Deacetylase Inhibition and Ataxia Telangiectasia Mutated (ATM) Activation and Methods of Use Thereof.'...The Company's HDAC pre-clinical inhibitor platform includes: SP-2-225 is Shuttle Pharma's pre-clinical Class IIb selective HDAC inhibitor that affects histone deacetylase HDAC6; SP-1-161 is Shuttle Pharma's pre-clinical candidate lead HDAC inhibitor, radiation sensitizing candidate product; SP-1-303 is Shuttle Pharma's pre-clinical selective Class I HDAC inhibitor..."

Patent • Breast Cancer • Estrogen Receptor Positive Breast Cancer • Hormone Receptor Positive Breast Cancer • Oncology • Solid Tumor